TA946 · STA

Olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab

Recommended for Cancer Drugs FundFebruary 2021

Source documents

Final Appraisal DocumentCommittee PapersScopeScope Consultation Comments

Interventions

bevacizumab (bevacizumab)
monoclonal antibody · Recombinant humanised monoclonal IgG1 antibody that inhibits vascular endothelial growth factor (VEGF) · Intravenous infusion
olaparib (Lynparza)
PARP inhibitor · PARP inhibitor · oral

Conditions

advanced ovarian, fallopian tube or primary peritoneal canceroncology · maintenance
advanced ovarian canceroncology · maintenance
fallopian tube canceroncology · maintenance
primary peritoneal canceroncology · maintenance

Comparators

NameType Established Committee preferred
bevacizumab monotherapyactive drug——
bevacizumab alone (placebo added to bevacizumab)active drugYes—

Clinical trials

TrialDesignPhasePivotal
PAOLA-1RCTIIIYes

Evidence gaps

immature overall survival—Immaturity of progression-free survival (PFS) and overall survival (OS) data at the time of appraisal
no uk data—Generalisability of data from the PAOLA-1 study to NHS population

Commercial arrangement

managed access agreement · confidential · critical for recommendation

Special considerations

Cancer Drugs Fund eligible